This company has been marked as potentially delisted and may not be actively trading. Cerecor (CERC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CERC vs. CNTA, ARWR, HRMY, GLPG, ARQT, IDYA, AGIO, IRON, ANIP, and EWTXShould you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include Centessa Pharmaceuticals (CNTA), Arrowhead Pharmaceuticals (ARWR), Harmony Biosciences (HRMY), Galapagos (GLPG), Arcutis Biotherapeutics (ARQT), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), Disc Medicine (IRON), ANI Pharmaceuticals (ANIP), and Edgewise Therapeutics (EWTX). These companies are all part of the "medical" sector. Cerecor vs. Centessa Pharmaceuticals Arrowhead Pharmaceuticals Harmony Biosciences Galapagos Arcutis Biotherapeutics IDEAYA Biosciences Agios Pharmaceuticals Disc Medicine ANI Pharmaceuticals Edgewise Therapeutics Centessa Pharmaceuticals (NASDAQ:CNTA) and Cerecor (NASDAQ:CERC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, community ranking, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Do institutionals & insiders believe in CNTA or CERC? 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.8% of Cerecor shares are owned by institutional investors. 11.6% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 45.7% of Cerecor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor CNTA or CERC? Cerecor received 151 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 74.00% of users gave Cerecor an outperform vote while only 60.71% of users gave Centessa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCentessa PharmaceuticalsOutperform Votes3460.71% Underperform Votes2239.29% CerecorOutperform Votes18574.00% Underperform Votes6526.00% Do analysts recommend CNTA or CERC? Centessa Pharmaceuticals currently has a consensus price target of $27.71, suggesting a potential upside of 100.97%. Given Centessa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Centessa Pharmaceuticals is more favorable than Cerecor.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Cerecor 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, CNTA or CERC? Centessa Pharmaceuticals has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Cerecor has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Which has stronger earnings & valuation, CNTA or CERC? Cerecor has lower revenue, but higher earnings than Centessa Pharmaceuticals. Cerecor is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M268.00-$151.09M-$1.99-6.93Cerecor$6.70M68.50-$63.50M-$0.57-8.39 Is CNTA or CERC more profitable? Centessa Pharmaceuticals has a net margin of 0.00% compared to Cerecor's net margin of -1,194.82%. Centessa Pharmaceuticals' return on equity of -52.13% beat Cerecor's return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -52.13% -38.01% Cerecor -1,194.82%-261.82%-133.96% Does the media prefer CNTA or CERC? In the previous week, Centessa Pharmaceuticals had 12 more articles in the media than Cerecor. MarketBeat recorded 12 mentions for Centessa Pharmaceuticals and 0 mentions for Cerecor. Centessa Pharmaceuticals' average media sentiment score of 1.08 beat Cerecor's score of 0.16 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Centessa Pharmaceuticals Positive Cerecor Neutral SummaryCentessa Pharmaceuticals beats Cerecor on 12 of the 18 factors compared between the two stocks. Get Cerecor News Delivered to You Automatically Sign up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERC vs. The Competition Export to ExcelMetricCerecorPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$458.92M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.30%P/E Ratio-8.397.1422.1418.40Price / Sales68.50238.89389.71101.29Price / CashN/A65.6738.2034.62Price / Book21.736.266.664.18Net Income-$63.50M$142.48M$3.21B$247.71M Cerecor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CERCCerecorN/A$4.78-2.0%N/A-67.4%$458.92M$6.70M-8.3931CNTACentessa Pharmaceuticals3.059 of 5 stars$12.66+4.2%$27.71+118.9%+54.4%$1.69B$6.85M-8.30200Insider TradeNews CoveragePositive NewsARWRArrowhead Pharmaceuticals3.5129 of 5 stars$12.17+0.7%$41.44+240.7%-39.4%$1.68B$2.50M-2.36400Positive NewsHRMYHarmony Biosciences4.6517 of 5 stars$28.89+1.4%$53.33+84.6%+2.4%$1.66B$714.73M13.71200Upcoming EarningsPositive NewsGLPGGalapagos0.6659 of 5 stars$25.09+1.8%$25.33+1.0%-6.2%$1.66B$275.65M0.001,310Earnings ReportAnalyst DowngradeNews CoverageARQTArcutis Biotherapeutics2.9205 of 5 stars$13.78+1.9%$18.80+36.4%+70.1%$1.64B$196.54M-7.73150Positive NewsIDYAIDEAYA Biosciences3.6403 of 5 stars$18.42+1.3%$53.58+190.9%-50.8%$1.62B$7M-5.6180Positive NewsAGIOAgios Pharmaceuticals3.8828 of 5 stars$28.19+3.1%$56.57+100.7%-7.0%$1.62B$36.50M2.49390Upcoming EarningsIRONDisc Medicine2.2299 of 5 stars$44.91+6.8%$93.80+108.9%+71.3%$1.55BN/A-11.2930News CoveragePositive NewsANIPANI Pharmaceuticals4.077 of 5 stars$69.37+2.0%$80.13+15.5%+7.5%$1.51B$614.38M-126.15600Analyst DowngradeNews CoveragePositive NewsEWTXEdgewise Therapeutics2.3766 of 5 stars$13.86+4.2%$40.13+189.6%-6.9%$1.46BN/A-9.3060Positive NewsGap Down Related Companies and Tools Related Companies Centessa Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Harmony Biosciences Alternatives Galapagos Alternatives Arcutis Biotherapeutics Alternatives IDEAYA Biosciences Alternatives Agios Pharmaceuticals Alternatives Disc Medicine Alternatives ANI Pharmaceuticals Alternatives Edgewise Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERC) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerecor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CERC Stock Free CERC Stock Alerts